Cetuximab-IRDye800CW (University Medical Center Groningen)

N/A

Report date: 2025/11/25 15:56:51

Base Information

Drug NameCetuximab-IRDye800CW (University Medical Center Groningen)
Drug Alias NameCetuximab-800cw
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsIonising radiation emitters
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsPenile NeoplasmsLung NeoplasmsRectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlandsItaly
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUmcg The University Medical Center Groningen
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Medical Center GroningenUniversity Of Turin
Inactive CompaniesN/A
Active IndicationsPenile NeoplasmsLung NeoplasmsRectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A